Aura Biosciences, Inc. Retained Earnings
Aura Biosciences, Inc. (AURA) had Retained Earnings of -$559.74 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$559.74M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$514.10M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$480.42M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$454.86M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$559.74M 10-Q · filed 2026-08-11 |
| 2026-03-31 | -$514.10M 10-Q · filed 2026-05-11 |
| 2025-12-31 | -$480.42M 10-Q · filed 2026-08-11 |
| 2025-09-30 | -$454.86M 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$428.73M 10-Q · filed 2025-08-13 |
| 2025-03-31 | -$401.71M 10-Q · filed 2025-05-15 |
| 2024-12-31 | -$374.23M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$348.39M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$327.35M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$307.01M 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$287.31M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$265.18M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$246.66M 10-Q · filed 2023-08-09 |
| 2023-03-31 | -$228.37M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$210.90M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$194.34M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$178.44M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$164.97M 10-Q · filed 2022-05-12 |
| 2021-12-31 | -$152.14M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$140.50M 10-Q · filed 2021-11-24 |
| 2020-12-31 | -$116.89M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |